Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 874 participants.

Also called NCT04217447

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 874 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04217447
Other papers using this trial's data
  • Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation The New England journal of medicine, 2025-10-23 DOI, PubMed 40888725

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT04217447. Randomized; quadruple masking; primary purpose treatment. Start 2020-05-25 (actual); primary completion 2024-10-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease
Acronym
AQUATIC
Intervention (Drug)
OAC + Aspirin 100mg od
Intervention (Drug)
OAC + placebo of Aspirin 100mg od
Lead sponsor
University Hospital, Brest (class: other)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct04217447
Content hash
a260dfaaae0d9ad1a9a54c4aa7d54a731483229d6a032d6e1f7e49ce1db013a2